e:Med

has the objective of promoting system-oriented research of diseases by linking life sciences and informatics and establishing a systems medicine network in Germany.

e:Med

has the objective of promoting system-oriented research of diseases by linking life sciences and informatics and establishing a systems medicine network in Germany.

e:Med

has the objective of promoting system-oriented research of diseases by linking life sciences and informatics and establishing a systems medicine network in Germany.

e:Med

has the objective of promoting system-oriented research of diseases by linking life sciences and informatics and establishing a systems medicine network in Germany.

A systems medicine network

e:Med has the objective of establishing systems medicine in Germany. e:Med promotes system-oriented research into diseases in order to facilitate improved prevention, more comprehensive diagnostics and individually adjusted therapy schemes in individualized medicine. The program brings together scientists with molecular-genetic, clinical, mathematical and information technology expertise, with the objective of ensuring that research results quickly benefit patients.
Electronic processing (e:Med) plays a particularly important role for unraveling scientific questions in iterative cycles of experimental studies and computer modelling approaches. The nationwide research and funding concept has been funded by the Federal Ministry of Education and Research (BMBF) since 2014.

Events and Highlights

Junior research alliances

Telltales of depression in our blood

Depression is a major cause of disability worldwide. Due to its complex nature, it is difficult to explain the molecular pathways associated with depression by examining the genetic factors. e:Med junior research alliance CKDNapp chose a metabolomics approach to tackle this problem. The results of their population-wide screen for metabolites revealed laurylcarnitine to be associated with depression. This metabolite is involved in the fatty acid oxidation pathway and may provide new therapy options against depression.

Highlight from the e:MedIUM Newsletter

Demonstrators

Hungry for glutamine – Understanding the metabolism of breast cancer

What to do when a cancer subtype can’t be targeted with drugs or hormones? Researchers of e:Med Her2low alliance focused their attention on understanding the metabolic needs of cancer cells. Their study revealed that cancer cells operate with altered metabolic and nutrient-sensing pathways to sustain tumorigenesis and these alterations might be targeted as a therapy approach

read more

e:Med

virtual e:Med Meeting on Systems Medicine 2021

The e: Med Meeting 2021 took place virtually from September 20-22, 2021 and covered a wide range of cutting-edge research topics in systems medicine. More than 300 participants took the opportunity to discuss their latest research results with their fellow scientists from the systems medicine community.

e:Med Meeting 2021

Junior Research Alliance

Analysis of Cancer Stem Cells with MutaSeq Open up New Research Possibilities

Scientists from the e:Med junior alliance LeukoSyStem have developed the method MutaSeq, that can distinguish cancer stem cells, mature cancer cells, and healthy stem cells based on their genetics. The method enables researchers to create highly detailed profiles of cancer cells, helping them understand every individual cell from a cancer. The result of this study opens up new possibilities in cancer research.

read more

Junior Research Alliance

A novel mechanism protects against cancer cell migration and neuron hyperexcitability

G3BP proteins inhibit the metabolic driver MTOR, a signaling protein that plays a central role in tumor diseases and developmental disorders of the brain. This is reported this week in the journal Cell by scientists of the BMBF-funded e:Med junior network GlioPATH together with a Europe-wide research network. G3BP proteins may serve as molecular markers to personalize therapies.

read more

Consortia

TreaT Urine Assay indicates transplant success

Success of a kidney transplant depends on how strongly the patient’s immune system reacts to the foreign cells. Scientists from the e:Med consortium e:Kid coordinated by Dr. Nina Babel have now developed the TreaT test, which uses cells from the patient's urine after a kidney transplantation to predict how well the recipient will tolerate the donor kidney. As a result, the accompanying immunosuppressive therapy can be adapted to each individual and over-medication can be prevented.

Highlight from the e:Med newsletter

Junior Research Alliances

A Metabolic Enzyme as a New Target for Cancer Immunotheraphy

Scientists from e:Med junior alliance GlioPATH discovered that the metabolic enzyme IL4I1 promotes the spread of tumour cells and suppresses the immune system.  IL4I1 is produced to a greater extent in tumours and activates the dioxin receptor. Agents that inhibit IL4I1 could open up new opportunities for cancer therapy in the future. The scientists have now published their results in the journal Cell.

 

 

read more

Junior Research Groups

Heterogeneous Tumors: Why one drug is often not enough

Tumors can behave differently in patients. This has already been well investigated and is a part of personalized-therapy concepts. The differences of a tumor within a patient are, however, less well known. These differences are called intratumoral heterogeneity. Heterogeneity can also influence the effectiveness of the therapy. In this project, e:Med scientists have inspected intratumoral differences and investigated transcription (scRNA-Seq), genetics and drug response in the different cells of B-cell lymphoma. The Heidelberg team could identify up to four different subpopulations within the same tumor, each of which reacted differently to specific drugs. These results show that intratumoral heterogeneity may be an important component of personalized therapy in the future.

read more

  •                                                      ...all highlights

Diese Seite nutzt Website Tracking-Technologien von Dritten, um ihre Dienste anzubieten. Ich bin damit einverstanden und kann meine Einwilligung jederzeit mit Wirkung für die Zukunft widerrufen oder ändern.

Einstellungen Akzeptieren ImpressumDatenschutz